GeoVax Labs (NASDAQ:GOVX) Given Buy Rating at HC Wainwright

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 206.51% from the company’s previous close.

A number of other brokerages also recently issued reports on GOVX. Noble Financial raised their price objective on GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a research report on Monday, August 19th. EF Hutton Acquisition Co. I upgraded shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd. Finally, Alliance Global Partners assumed coverage on shares of GeoVax Labs in a report on Monday. They issued a “buy” rating and a $15.00 price objective on the stock. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $13.25.

GeoVax Labs Stock Down 3.3 %

Shares of GOVX stock opened at $2.61 on Friday. The firm’s 50-day moving average is $2.39 and its two-hundred day moving average is $2.59. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same quarter in the prior year, the company posted ($4.80) earnings per share. As a group, equities analysts predict that GeoVax Labs will post -5.1 EPS for the current fiscal year.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.